Medical technology group Getinge has seen downward revisions to its earnings estimates following its April 21 report, while the average target price remains largely unchanged.

The stock, which fell 1.3 percent on the day of the report, is currently down 6.5 percent since the release, while the blue-chip OMXS30 index has gained 0.2 percent.

Factset consensus for Getinge has been adjusted downwards post-report. Sales estimates for the current year have been trimmed by 1.0 percent to SEK 34,854 million, while the forecast for next year has been lowered by 0.9 percent to SEK 36,530 million. Profitability estimates have also been revised lower, with adjusted EBITA for the current year cut by 1.8 percent to SEK 4,944 million and next year's forecast reduced by 1.4 percent to SEK 5,555 million.

The consensus recommendation remains at Overweight. The average target price stands at SEK 224.55, representing an upside of approximately 19.6 percent compared to the current share price.

The distribution of recommendations is unchanged following the report. The proportion of positive recommendations stands at 42 percent, while 50 percent are neutral and 8 percent are negative. Prior to the report, the distribution was also 42 percent positive, 50 percent neutral, and 8 percent negative.

Getinge
Share price performance on reporting day-1.3%
Date2026-05-072026-04-20DifferenceNumber of estimates
Share price187.75200.90-6.5%
Average target price224.55225.64-0.5%
Spread target price vs current share price19.60%12.31%
Consensus recommendationOverweightOverweight12
Share of positive recommendations42%42%5
Share of hold recommendations50%50%6
Share of negative recommendations8%8%1
Sales, current year34 85435 197-1.0%10
Sales, next year36 53036 868-0.9%10
Sales growth, next year4.8%4.7%
Adjusted EBITA, current year4 9445 033-1.8%8
Adjusted EBITA, next year5 5555 633-1.4%8
Adjusted EBITA growth, next year12.3%11.9%
Source: Factset